接受 CAR-T 细胞治疗的大 B 细胞淋巴瘤患者毒性与疗效的胚系决定因素

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.

与髓系细胞生物学相关的胚系遗传异常可预测 LBCL 患者中 CAR-T 的毒性和疗效。

口服甘草酸二铵减轻毒性并增强 CAR-T 细胞治疗疗效的研究

Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy

这是一项 II/III 期注册临床试验，评估细胞治疗用于大 B 细胞淋巴瘤的安全性、可行性及初步疗效。当前状态：尚未开始招募。计划入组 21 例。登记号：NCT07616271。

CLO26-108：CAR-T 细胞治疗结外和结内大 B 细胞淋巴瘤的疗效

CLO26-108: Efficacy of CAR T Cell Therapy in Extranodal and Nodal Large B-Cell Lymphoma.

低强度 I 型干扰素信号促进 CAR-T 细胞治疗疗效

Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.

R/R DLBCL 中 CAR-T 细胞治疗期间的标准化 FDG-PET 判读：一项 DESCAR-T 研究

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.

基线的 TMTV 和通过 DS 评估的代谢反应，以及随访 PET/CT 上的残留 TMTV，是接受 anti-CD19 CAR T-cells 治疗的 R/R DLBCL 患者强有力的预后生物标志物。

氟达拉滨剂量对接受 CAR-T 细胞治疗的大 B 细胞淋巴瘤患者结局的影响：EBMT 的 CTIWP 一项回顾性研究

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the

二线 CAR-T 细胞治疗后进展的大 B 细胞淋巴瘤的结局与挽救策略：LYSA 集团的 DESCAR-T 研究

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

新型无严重毒性且无进展生存期终点预测大 B 细胞淋巴瘤 CD19 CAR-T 细胞治疗后的结局

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-

Glofitamab 联合 Polatuzumab Vedotin 治疗复发/难治性大 B 细胞淋巴瘤（包括高级别 B 细胞淋巴瘤）的疗效与安全性：Ib/II 期试验结果

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results

Glofit-Pola 在经多线治疗的 R/R LBCL 患者中显示出高疗效和持久缓解，安全性可控，其中包括 HGBCL 患者和既往 CAR-T 细胞治疗失败的患者。

去甲基化预处理的串联 CD19/CD20 CAR-T 细胞治疗复发/难治性 B 细胞淋巴瘤：一项 I/II 期试验

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.